DiaMedica Therapeutics (DMAC) Long-Term Investments (2023 - 2025)

DiaMedica Therapeutics (DMAC) posted quarterly Long-Term Investments of $1.0 million for Q1 2025, down 89.74% quarter-over-quarter from $9.7 million in Q3 2023.

DiaMedica Therapeutics (DMAC) Long-Term Investments (2023 - 2025) Analysis & Trends

DiaMedica Therapeutics' Long-Term Investments history runs 2 years deep, the most recent figure standing at $1.0 million for Q1 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Investments (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 5.79 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 9.83 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn -
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - 372.10 Mn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 22.17 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -
10 DiaMedica Therapeutics 360.22 Mn 360.22 Mn - -

Historic Data

Download Data
DateValue
Mar 31, 2025 1.00 Mn
Sep 30, 2023 9.75 Mn
Jun 30, 2023 20.30 Mn